Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00330252
Status:
COMPLETED
Last Update Posted:
2016-05-13
First Post:
2006-05-25
Brief Title:
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
05-404
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Jennifer R Brown MD PhD
Responsible Party Title:
Assistant Professor of Medicine
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Genzyme a Sanofi Company | INDUSTRY |